search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Australasian Biotechnology (backfiles)
AusBiotech
ISSN: 1036-7128
Vol. 12, No. 2, 2002, pp. 33-34
Bioline Code: au02013
Full paper language: English
Document type: Research Article
Document available free of charge

Australasian Biotechnology (backfiles), Vol. 12, No. 2, 2002, pp. 33-34

 en CLINICAL STUDIES - WHAT YOU DON'T KNOW WILL HURT YOU! AUSTRALIAN BIOTECH - 'IN THE KNOW' WITH CLINICAL TRIALS?
Karen Woolley and Mark Woolley

Abstract

Clinical research is the most expensive and longest phase of drug development. A loss of one million dollars (US) is incurred for every day of delay in developing a successful drug. Therefore, clinical trials must be conducted efficiently to optimise drug development. Data from the US, however, indicates that timelines for clinical trials of biopharmaceuticals have become progressively worse. In contrast, the timelines for clinical trials of new chemical entities have become progressively better. While relatively few Australian biotechnology companies have advanced compounds to the clinical trial stage, companies will need to develop strategies to ensure clinical trials are conducted efficiently. Australian biotech companies need to focus on planning, processes, people and partners and may benefit from lessons learned by large pharmaceutical companies ('Big Pharma').

 
© Copyright 2002 - AusBiotech
Alternative site location: http://www.ausbiotech.org/content.asp?pageid=16

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2020, Site last up-dated on 28-Nov-2020.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil